-+ 0.00%
-+ 0.00%
-+ 0.00%
Denali Therapeutics Swings to Q3 2026 Net Income of $70.13 Million
Share
Listen to the news
Denali Therapeutics Swings to Q3 2026 Net Income of $70.13 Million
  • Denali Therapeutics swung to third-quarter 2026 net income of $70.1 million, including a one-time $194 million Priority Review Voucher sale net gain.
  • AVLAYAH net product revenue reached $17.8 million in its second full commercial quarter.
  • Zafinofusp alfa remains on track for a 2027 BLA submission seeking accelerated approval for Sanfilippo syndrome type A.
  • Fourth-quarter 2026 net product revenue is expected to reach $30 million to $32 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031601PRIMZONEFULLFEED9869427) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending